New Delhi: The Serum Institute of India (SII) has sought emergency use authorisation of its vaccine candidate Covishield in the country.
The Pune-based SII is conducting the India trials of Covishield vaccine developed by AstraZeneca and Oxford University.
In in its application to the the Drug Controller General of India (DCGI), SII cited “unmet medical needs due to the pandemic and in the interest of the public at large” as the reason for seeking emergency authorisation of the vaccine emergency use approval.
Earlier, Pfizer India became the first pharmaceutical firm to seek emergency use authorisation for its COVID-19 vaccine candidate in the country.
New Delhi: Saif Ali and Amrita Singh's son, Ibrahim Ali Khan finally made his Instagram…
Rourkela: An under-trial prisoner (UTP) died while undergoing treatment at a hospital while his family…
New Delhi: The Supreme Court on Tuesday questioned the Enforcement Directorate (ED) on the timing…
Pune: Odisha recently bagged two silver medals in the 67th National School Games Rugby U-17…
Ranchi: Odisha made a victorious start in the 1st National Women's Hockey League (Phase-1) 2024-25,…
New Delhi: Prajwal Revanna, Karnataka MP and former Prime Minister HD Deve Gowda’s grandson, was…
New Delhi: The BCCI has announced India's 15-member squad for the upcoming ICC Men’s T20…
Cuttack: Odisha Vigilance sleuths on Tuesday apprehended Reshma Majhi, Assistant Revenue Inspector and In-charge Revenue…